Derrell D. Porter, M.D.

CEO: cTRL Therapeutics, Inc.

Dr. Porter is a physician-entrepreneur with more than 20 years of experience in drug development and commercialization. He is currently the CEO of cTRL Therapeutics, a next generation cell therapy company focused on solid tumors, leveraging circulating tumor reactive lymphocytes. Previously, he was founder and CEO of Cellevolve Bio, a development and commercialization cell therapy biotech focused on neglected diseases. Additionally, he served in commercial, strategy and corporate development roles at Atara Bio, Gilead, AbbVie and Amgen. He is also a Board Member at Passage Bio, a genetics medicine company developing therapeutics for disorders of the central nervous system and Portal Innovations, LLC, a venture development engine which delivers seed capital, specialized equipment, lab space, and management expertise to early-stage biotech companies.

Dr. Porter started his career at McKinsey & Company where he worked with multiple biopharmaceutical clients. He earned his M.D. from the Perelman School of Medicine and MBA from the Wharton School at the University of Pennsylvania, and his B.S. in Neuroscience from the University of California, Los Angeles.